Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bader, Ted, M.D.
• Collaborators: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Fluvastatin; Interferons; Ribavirin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Not previously treated.

• Off alcohol and marijuana for 6 months

• HCV RNA positive

Exclusion Criteria:

• HIV positive

• Advanced liver disease

• Advanced cardiopulmonary disease

• Chronic renal failure